Literature DB >> 26940997

Atorvastatin blocks increased l-type Ca2+ current and cell injury elicited by angiotensin II via inhibiting oxide stress.

Yanzhuo Ma1, Lingfeng Kong2, Shuying Qi1, Dongmei Wang3.   

Abstract

Thel-type Ca(2+)current (ICa,l) plays a crucial role in shaping action potential and is involved in cardiac arrhythmia. Statins have been demonstrated to contribute to anti-apoptotic and anti-arrhythmic effects in the heart. Here, we examined whether atorvastatin regulates theICa,land cell injury induced by angiotensin II (AngII) as well as the putative intracellular cascade responsible for the effects. Cultured neonatal rat ventricular myocytes were incubated with AngII for 24 h, and then cell injury and expression levels of Nox2/gp91(phox), p47(phox) ,and Cav1.2 were analyzed. In addition,ICa,lwas recorded using the whole-cell patch-clamp technique, and mechanisms of atorvastatin actions were also investigated. It was found that the number of apoptotic cardiomyocytes was increased and cell viability was significantly decreased after AngII administration. AngII also augmented the expressions of Nox2/gp91(phox)and p47(phox)compared with control cardiomyocytes. Exposure to AngII evokedICa,lin a voltage-dependent manner without affecting theI-Vrelationship. In addition, AngII enhanced membrane Cav1.2 expression. These effects were abolished in the presence of the reactive oxygen species (ROS) scavenger, manganese (III)-tetrakis 4-benzoic acid porphyrin [Mn(III)TBAP], or the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, atorvastatin. These results suggested that atorvastatin mediates cardioprotection against arrhythmias and cell injury by controlling the AngII-ROS cascade.
© The Author 2016. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  angiotensin II; apoptosis; atorvastatin; l-type Ca2+ current

Mesh:

Substances:

Year:  2016        PMID: 26940997      PMCID: PMC4886248          DOI: 10.1093/abbs/gmw009

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  28 in total

Review 1.  Cardiac excitation-contraction coupling.

Authors:  Donald M Bers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

2.  The three-dimensional structure of the cardiac L-type voltage-gated calcium channel: comparison with the skeletal muscle form reveals a common architectural motif.

Authors:  Ming-Chuan Wang; Richard F Collins; Robert C Ford; Nicholas S Berrow; Annette C Dolphin; Ashraf Kitmitto
Journal:  J Biol Chem       Date:  2003-11-22       Impact factor: 5.157

3.  Angiotensin II stimulates cardiac L-type Ca(2+) current by a Ca(2+)- and protein kinase C-dependent mechanism.

Authors:  E A Aiello; H E Cingolani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-04       Impact factor: 4.733

4.  Redox sensing properties of the ryanodine receptor complex.

Authors:  Isaac N Pessah; Kyung Ho Kim; Wei Feng
Journal:  Front Biosci       Date:  2002-05-01

5.  HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density.

Authors:  D F Gray; H Bundgaard; P S Hansen; K A Buhagiar; A S Mihailidou; W Jessup; K Kjeldsen; H H Rasmussen
Journal:  Cardiovasc Res       Date:  2000-08       Impact factor: 10.787

6.  Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery.

Authors:  Andreas Bergdahl; Erik Persson; Per Hellstrand; Karl Swärd
Journal:  Pharmacol Toxicol       Date:  2003-09

7.  Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment.

Authors:  Christoph Maack; Tanja Kartes; Heiko Kilter; Hans-Joachim Schäfers; Georg Nickenig; Michael Böhm; Ulrich Laufs
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

9.  Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.

Authors:  Nihal Ozturk; Nazmi Yaras; Asli Ozmen; Semir Ozdemir
Journal:  J Bioenerg Biomembr       Date:  2013-05-03       Impact factor: 2.945

10.  Acute simvastatin inhibits K ATP channels of porcine coronary artery myocytes.

Authors:  Sai Wang Seto; Alice Lai Shan Au; Christina Chui Wa Poon; Qian Zhang; Rachel Wai Sum Li; John Hok Keung Yeung; Siu Kai Kong; Sai Ming Ngai; Song Wan; Ho Pui Ho; Simon Ming Yuen Lee; Maggie Pui Man Hoi; Shun Wan Chan; George Pak Heng Leung; Yiu Wa Kwan
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

View more
  5 in total

1.  Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction.

Authors:  Jingbin Yu; Lei Zhang; Hui Zhang
Journal:  Exp Ther Med       Date:  2020-01-27       Impact factor: 2.447

Review 2.  Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress.

Authors:  Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 3.  Antioxidants in Arrhythmia Treatment-Still a Controversy? A Review of Selected Clinical and Laboratory Research.

Authors:  Jakub Szyller; Dariusz Jagielski; Iwona Bil-Lula
Journal:  Antioxidants (Basel)       Date:  2022-06-02

Review 4.  Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes.

Authors:  Basil S Karam; Alejandro Chavez-Moreno; Wonjoon Koh; Joseph G Akar; Fadi G Akar
Journal:  Cardiovasc Diabetol       Date:  2017-09-29       Impact factor: 9.951

5.  Angiotensin II upregulates cyclophilin A by enhancing ROS production in rat cardiomyocytes.

Authors:  Hangyu Tian; Dan Yu; Yan Hu; Pan Zhang; Yang Yang; Qiang Hu; Ming Li
Journal:  Mol Med Rep       Date:  2018-09-04       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.